{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:53:38Z","timestamp":1788314018943,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN2722017000311"],"award-info":[{"award-number":["HHSN2722017000311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MVA-based monovalent eastern equine encephalitis virus (MVA-BN-EEEV) and multivalent western, eastern, and Venezuelan equine encephalitis virus (MVA-BN-WEV) vaccines were evaluated in the cynomolgus macaque aerosol model of EEEV infection. Macaques vaccinated with two doses of 5 \u00d7 10<jats:sup>8<\/jats:sup> infectious units of the MVA-BN-EEEV or MVA-BN-WEV vaccine by the intramuscular route rapidly developed robust levels of neutralizing antibodies to EEEV that persisted at high levels until challenge at day 84 via small particle aerosol delivery with a target inhaled dose of 10<jats:sup>7<\/jats:sup> PFU of EEEV FL93-939. Robust protection was observed, with 7\/8 animals receiving MVA-BN-EEEV and 100% (8\/8) animals receiving MVA-BN-WEV surviving while only 2\/8 mock vaccinated controls survived lethal challenge. Complete protection from viremia was afforded by both vaccines, with near complete protection from vRNA loads in tissues and any pathologic evidence of central nervous system damage. Overall, the results indicate both vaccines are effective in eliciting an immune response that is consistent with protection from aerosolized EEEV-induced disease.<\/jats:p>","DOI":"10.1038\/s41541-024-00842-y","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T12:02:59Z","timestamp":1709035379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-1304","authenticated-orcid":false,"given":"Brandon J.","family":"Beddingfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-3167","authenticated-orcid":false,"given":"Kenneth S.","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4768-7458","authenticated-orcid":false,"given":"Jessica A.","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-8556","authenticated-orcid":false,"given":"Scott C.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Krzykwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chirichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-0707","authenticated-orcid":false,"given":"Rachel K.","family":"Redmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Z.","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Endt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Maness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-6974","authenticated-orcid":false,"given":"Chad J.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.antiviral.2012.04.002","volume":"94","author":"SC Weaver","year":"2012","unstructured":"Weaver, S. C., Winegar, R., Manger, I. D. & Forrester, N. L. Alphaviruses: population genetics and determinants of emergence. Antiviral Res. 94, 242\u2013257 (2012).","journal-title":"Antiviral Res"},{"key":"842_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","volume":"140","author":"MA Zacks","year":"2010","unstructured":"Zacks, M. A. & Paessler, S. Encephalitic alphaviruses. Vet Microbiol 140, 281\u2013286 (2010).","journal-title":"Vet Microbiol"},{"key":"842_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0891-5520(20)30389-5","volume":"5","author":"TF Tsai","year":"1991","unstructured":"Tsai, T. F. Arboviral infections in the United States. Infect. Dis. Clin. North Am. 5, 73\u2013102 (1991).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"842_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0025-7125(16)30270-X","volume":"77","author":"JF Bale Jr.","year":"1993","unstructured":"Bale, J. F. Jr. Viral encephalitis. Med. Clin. North Am. 77, 25\u201342 (1993).","journal-title":"Med. Clin. North Am."},{"key":"842_CR5","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMp1914328","volume":"381","author":"DM Morens","year":"2019","unstructured":"Morens, D. M., Folkers, G. K. & Fauci, A. S. Eastern Equine Encephalitis Virus - Another emergent arbovirus in the United States. N. Engl. J. Med. 381, 1989\u20131992 (2019).","journal-title":"N. Engl. J. Med."},{"key":"842_CR6","unstructured":"CDC. Centers for Disease Control and Prevention-Bioterrorism Agents\/Diseases, https:\/\/emergency.cdc.gov\/agent\/agentlist-category.asp (2022)."},{"key":"842_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.15585\/mmwr.mm6902a4","volume":"69","author":"NP Lindsey","year":"2020","unstructured":"Lindsey, N. P., Martin, S. W., Staples, J. E. & Fischer, M. Notes from the field: multistate outbreak of Eastern Equine Encephalitis Virus - United States, 2019. MMWR Morb. Mortal Wkly. Rep. 69, 50\u201351 (2020).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"842_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coviro.2020.05.001","volume":"40","author":"MA Robert","year":"2020","unstructured":"Robert, M. A., Stewart-Ibarra, A. M. & Estallo, E. L. Climate change and viral emergence: evidence from Aedes-borne arboviruses. Curr. Opin. Virol. 40, 41\u201347 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"842_CR9","doi-asserted-by":"crossref","unstructured":"Pittman, P. R. & Plotkin, S. A. In Plotkin\u2019s Vaccines (eds S A. Plotkin, W A. Orenstein, P A. Offit, & KM. Edwards) 149-160.e147 (Elsevier, 2018).","DOI":"10.1016\/B978-0-323-35761-6.00012-2"},{"key":"842_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7205\/MILMED.170.4S.92","volume":"170","author":"CH Hoke Jr.","year":"2005","unstructured":"Hoke, C. H. Jr. History of U.S. military contributions to the study of viral encephalitis. Mil. Med. 170, 92\u2013105 (2005).","journal-title":"Mil. Med."},{"key":"842_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","volume":"14","author":"PR Pittman","year":"1996","unstructured":"Pittman, P. R. et al. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14, 337\u2013343 (1996).","journal-title":"Vaccine"},{"key":"842_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.4269\/ajtmh.1963.12.597","volume":"12","author":"RW McKinney","year":"1963","unstructured":"McKinney, R. W., Berge, T. O., Sawyer, W. D., Tigertt, W. D. & Crozier, D. Use of an attenuated strain of Venezuelan Equine Encephalomyelitis virus for immunization in man. Am. J. Trop. Med. Hyg. 12, 597\u2013603 (1963).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"842_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1128\/jcm.19.3.429-431.1984","volume":"19","author":"PB Jahrling","year":"1984","unstructured":"Jahrling, P. B. & Stephenson, E. H. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J. Clin. Microbiol. 19, 429\u2013431 (1984).","journal-title":"J. Clin. Microbiol."},{"key":"842_CR14","doi-asserted-by":"publisher","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","volume":"27","author":"S Paessler","year":"2009","unstructured":"Paessler, S. & Weaver, S. C. Vaccines for Venezuelan equine encephalitis. Vaccine 27, D80\u2013D85 (2009).","journal-title":"Vaccine"},{"key":"842_CR15","doi-asserted-by":"publisher","unstructured":"Spurgers, K. B. & Glass, P. J. Vaccine development for Biothreat Alpha viruses. J. Bioterrorism Biodefense 01. https:\/\/doi.org\/10.4172\/2157-2526.S1-001 (2011)","DOI":"10.4172\/2157-2526.S1-001"},{"key":"842_CR16","first-page":"24","volume":"195","author":"A Mayr","year":"1964","unstructured":"Mayr, A. & Munz, E. [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]. Zentralbl. Bakteriol. Orig. 195, 24\u201335 (1964).","journal-title":"Zentralbl. Bakteriol. Orig."},{"key":"842_CR17","first-page":"375","volume":"167","author":"A Mayr","year":"1978","unstructured":"Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)]. Zentralbl. Bakteriol. B 167, 375\u2013390 (1978).","journal-title":"Zentralbl. Bakteriol. B"},{"key":"842_CR18","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","volume":"27","author":"M Suter","year":"2009","unstructured":"Suter, M. et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 27, 7442\u20137450 (2009).","journal-title":"Vaccine"},{"key":"842_CR19","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","volume":"19","author":"KJ Stittelaar","year":"2001","unstructured":"Stittelaar, K. J. et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19, 3700\u20133709 (2001).","journal-title":"Vaccine"},{"key":"842_CR20","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","volume":"31","author":"SE Frey","year":"2013","unstructured":"Frey, S. E. et al. Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario. Vaccine 31, 3025\u20133033 (2013).","journal-title":"Vaccine"},{"key":"842_CR21","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","volume":"32","author":"SE Frey","year":"2014","unstructured":"Frey, S. E. et al. Phase II randomized, double-blinded comparison of a single high dose (5x10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1x10(8) TCID50) in healthy vaccinia-naive individuals. Vaccine 32, 2732\u20132739 (2014).","journal-title":"Vaccine"},{"key":"842_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","volume":"28","author":"A von Krempelhuber","year":"2010","unstructured":"von Krempelhuber, A. et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28, 1209\u20131216 (2010).","journal-title":"Vaccine"},{"key":"842_CR23","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","volume":"25","author":"SE Frey","year":"2007","unstructured":"Frey, S. E. et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 25, 8562\u20138573 (2007).","journal-title":"Vaccine"},{"key":"842_CR24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","volume":"381","author":"PR Pittman","year":"2019","unstructured":"Pittman, P. R. et al. Phase 3 efficacy trial of modified Vaccinia Ankara as a vaccine against Smallpox. N. Engl. J. Med. 381, 1897\u20131908 (2019).","journal-title":"N. Engl. J. Med."},{"key":"842_CR25","doi-asserted-by":"publisher","first-page":"e0274906","DOI":"10.1371\/journal.pone.0274906","volume":"17","author":"V Bockstal","year":"2022","unstructured":"Bockstal, V. et al. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. PLoS One 17, e0274906 (2022).","journal-title":"PLoS One"},{"key":"842_CR26","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2018.06.064","volume":"36","author":"WG Hu","year":"2018","unstructured":"Hu, W. G. et al. Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses. Vaccine 36, 5194\u20135203 (2018).","journal-title":"Vaccine"},{"key":"842_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598847","volume":"11","author":"L Henning","year":"2020","unstructured":"Henning, L., Endt, K., Steigerwald, R., Anderson, M. & Volkmann, A. A Monovalent and trivalent MVA-based vaccine completely protects mice against lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol challenge. Front. Immunol. 11, 598847 (2020).","journal-title":"Front. Immunol."},{"key":"842_CR28","doi-asserted-by":"publisher","first-page":"e1009308","DOI":"10.1371\/journal.ppat.1009308","volume":"17","author":"JR Albe","year":"2021","unstructured":"Albe, J. R. et al. Physiological and immunological changes in the brain associated with lethal eastern equine encephalitis virus in macaques. PLoS Pathog. 17, e1009308 (2021).","journal-title":"PLoS Pathog"},{"key":"842_CR29","doi-asserted-by":"publisher","unstructured":"Jordan, E. et al. Reduced respiratory syncytial virus load, symptoms, and infections: a human challenge trial of MVA-BN-RSV vaccine. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiad108 (2023)","DOI":"10.1093\/infdis\/jiad108"},{"key":"842_CR30","doi-asserted-by":"publisher","unstructured":"Wong, Y. C. et al. Modified Vaccinia Virus Ankara can induce optimal CD8(+) T cell responses to directly primed antigens depending on vaccine design. J. Virol. 93. https:\/\/doi.org\/10.1128\/JVI.01154-19 (2019)","DOI":"10.1128\/JVI.01154-19"},{"key":"842_CR31","doi-asserted-by":"publisher","unstructured":"Ko, S. Y. et al. A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. Sci. Transl. Med. 11. https:\/\/doi.org\/10.1126\/scitranslmed.aav3113 (2019)","DOI":"10.1126\/scitranslmed.aav3113"},{"key":"842_CR32","doi-asserted-by":"publisher","first-page":"12077","DOI":"10.1128\/JVI.01406-14","volume":"88","author":"DS Reed","year":"2014","unstructured":"Reed, D. S. et al. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses. J. Virol. 88, 12077\u201312086 (2014).","journal-title":"J. Virol."},{"key":"842_CR33","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.vaccine.2013.01.014","volume":"31","author":"CJ Roy","year":"2013","unstructured":"Roy, C. J. et al. A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus. Vaccine 31, 1464\u20131470 (2013).","journal-title":"Vaccine"},{"key":"842_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/0976-500X.72351","volume":"1","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J. Pharmacol. Pharmacother. 1, 94\u201399 (2010).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"842_CR35","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1128\/JVI.02514-07","volume":"82","author":"PV Aguilar","year":"2008","unstructured":"Aguilar, P. V. et al. Structural and nonstructural protein genome regions of eastern equine encephalitis virus are determinants of interferon sensitivity and murine virulence. J. Virol. 82, 4920\u20134930 (2008).","journal-title":"J. Virol."},{"key":"842_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.vascn.2003.07.001","volume":"49","author":"JM Hartings","year":"2004","unstructured":"Hartings, J. M. & Roy, C. J. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J. Pharmacol. Toxicol. Methods 49, 39\u201355 (2004).","journal-title":"J. Pharmacol. Toxicol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00842-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T12:04:59Z","timestamp":1709035499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00842-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00842-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kathrin Endt and Ariane Volkmann are employees of Bavarian Nordic GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}